Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Book

Amyloidosis

In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan.
.
Affiliations
Free Books & Documents
Book

Amyloidosis

Jean G. Bustamante et al.
Free Books & Documents

Excerpt

Amyloidosis is a heterogeneous disease that results from the deposition of toxic insoluble beta-sheet fibrillar protein aggregates in different tissues. Amyloidosis can be acquired or hereditary. The disease can be localized or systemic. Amyloid can accumulate in the liver, spleen, kidney, heart, nerves, and blood vessels, causing different clinical syndromes, including cardiomyopathy, hepatomegaly, proteinuria, macroglossia, autonomic dysfunction, ecchymoses, neuropathy, renal failure, hypertension, and corneal and vitreous abnormalities.

Previously multiple classification systems have been devised to classify different types of amyloidosis. In modern times it has been classified according to the chemical analysis of amyloid clinical entities. Amyloidosis can be classified according to systemic, hereditary, central nervous system, ocular, and localized etiology. However, the most common types are AL, AA, ATTR (amyloid transport protein transthyretin), and dialysis-related amyloidosis (beta2M type).

In AL amyloidosis, 'A' represents amyloid followed by the associated fibrillar protein, 'L' means light chain fragment or immunoglobulin light chain. In AA amyloidosis, the second A stands for the serum amyloid A protein.

PubMed Disclaimer

Conflict of interest statement

Disclosure: Jean Bustamante declares no relevant financial relationships with ineligible companies.

Disclosure: Syed Rafay Zaidi declares no relevant financial relationships with ineligible companies.

References

    1. Tini G, Vianello PF, Gemelli C, Grandis M, Canepa M. Amyloid Cardiomyopathy in the Rare Transthyretin Tyr78Phe Mutation. J Cardiovasc Transl Res. 2019 Dec;12(6):514-516. - PubMed
    1. Baiardi S, Rossi M, Capellari S, Parchi P. Recent advances in the histo-molecular pathology of human prion disease. Brain Pathol. 2019 Mar;29(2):278-300. - PMC - PubMed
    1. Gavriatopoulou M, Fotiou D, Ntanasis-Stathopoulos I, Kastritis E, Terpos E, Dimopoulos MA. How I treat elderly patients with plasma cell dyscrasias. Aging (Albany NY) 2018 Dec 18;10(12):4248-4268. - PMC - PubMed
    1. Thomas VE, Smith J, Benson MD, Dasgupta NR. Amyloidosis: diagnosis and new therapies for a misunderstood and misdiagnosed disease. Neurodegener Dis Manag. 2019 Dec;9(6):289-299. - PubMed
    1. Sipe JD, Benson MD, Buxbaum JN, Ikeda S, Merlini G, Saraiva MJ, Westermark P, Nomenclature Committee of the International Society of Amyloidosis Amyloid fibril protein nomenclature: 2012 recommendations from the Nomenclature Committee of the International Society of Amyloidosis. Amyloid. 2012 Dec;19(4):167-70. - PubMed

Publication types

LinkOut - more resources